📣 Updated ESMO #ClinicalPracticeGuideline on local & locoregional #ProstateCancer: ✅New imaging modalities: improved diagnosis, staging & risk stratification ✅Updated algorithms: less over-Tx & fewer side-effects #Oncology #UroOncology #CancerCare #ESMOGuidelines 🔗

Just out in @TheLancet: an overview on current approaches to diagnosis and management of prostate cancer. https://t.co/AhomCOFkZg

What a lovely memento of the #BLADDR25 family. Looking forward to #BLADDR26 in #Amsterdam - come & join us - Dec 2-5 2026! @mirrorsmed @issecam #PROSCA25 #RENALC25

DEAR COLLEAGUES A reminder that #APCCC26 🇨🇭is coming in 2026 This is a Conference is OPEN TO EVERYONE, not just the Panel members and EARLY REGISTRATION is up until February 28, 2026 Awarm invite to the Advanced Prostate Cancer Consensus Conference #APCCC26 in Lugano🇨🇭

Four years of hard work were rewarded yesterday with a wonderful PhD and PhD defence by @FlorVerghote ! The results of this research contribute to a better understanding of the role of radiotherapy in bladder cancer. Proud to have been your supervisor with @CharlesPraet !

Honoured to had the opportunity to discuss the place of Adjuvant Radiotherapy for bladder Cancer and presenting the results of the Belgian trial supporting this approach! Motivated to proceed with our ongoing EFFORT trial! @FlorVerghote @camilleberquin @daandm @uzgent @ugent

High-risk biochemical recurrence with positive PSMA PET: Radiotherapy still matters. Presentation by @fontev1 @uzgent. #EAU25 written coverage by @RKSayyid @USC > https://t.co/8z3690IrF5 @Uroweb

I usually don’t post political views but now….

Updated results by @FlorVerghote of the Belgian trial on Adjuvant Radiotherapy for MIBC! Awaiting the results of the trials by @PaulSargos and @VedangMurthy @ugent @uzgent @camilleberquin @CharlesPraet @Xristodouleas @BrianBaumannMD https://t.co/7Vowx2JjTj

Does SBRT for oligorecurrent #prostatecancer improve overall survival as compared to SOC? WOLVERINE reporting on STOMP, ORIOLE, EXTEND and ARTO. Presented by @ChadTangMD at #GU25.

Recap of a first excellent day of the Belgian Urology Conference in Spa! Kudos to @AFSpinoit for the great organization! And endlessly proud of our team 💪🏽 @uzgent @ugent_fge @DrHerve_urology @CharlesPraet @mwaterloos1 @fontev1 #BAU24

@drenriquegrande @urotoday @DrOmarMian @fredhutch @RKSayyid For sure underutilized. ⚡ Safe and efficient with many prospective data available.. And many to come! @VedangMurthy @jnt_khalifa @fontev1 @BrianBaumannMD @Xristodouleas @GETUG_Unicancer

A great Pleasure to Present our paper on Management of patients with Advanced #ProstateCancer : A Report from #APCCC24 LINK TO ARTICLE👇👇👇👇👇👇👇👇 https://t.co/dyTV0eN9zy The 2024 Advanced Prostate Cancer Consensus Conference (APCCC) highlights significant advances in

We learned a lot about muscle-invasive bladder cancer this past week. Together, these studies suggest that a strategy worth exploring is to further de-intensify surgical lymph node management to reduce surgery-related mortality, while using adjuvant radiation to treat nodes in

Interested in reading the protocol? https://t.co/tyDavqw1zI Interested in the early results? Coming soon at a conference near you! #BladderCancerAwarenessMonth 🧡 @BladderCancerUK @BladderCancerUS @UroDocAsh @shilpaonc @neerajaiims @fontev1

#ESTRO24 @FlorVerghote adding to the emerging role of adjuvant RT for bladder cancer Intriguing that only 3/14 pts with positive surgical margins had pelvic failures #radonc

@joniau @MaartenAlbersen @DrShariat @tompowles1 @ThRoumeguere @KarelDecaestec1 @fontev1 @LoicBaekelandt @GertMeerleer @BertrandTOMBAL @LorenzoTOSCO @KatoRans @Eduardrssl @ESRUrology @BVUrologie @sb_uro

3-year toxicity after moderate hypofractionated radiotherapy: a Belgian phase 3 trial adding to the evidence that moderate hypofractionated radiotherapy is feasible in unselected prostate cancer patients. Teamwork @uzgent @Universiteit Gent https://t.co/w9uF5iA69d

Is there a role for stereotactic radiotherapy in selected patients with metastatic castrate-resistant #ProstateCancer? Check out this presentation by @fontev1 @ugent. #GU24 written coverage by @RKSayyid @UofT on UroToday > https://t.co/sTTPmqTgij @ASCO

Looking forward to present at #GU24: Treatment intensification: what to do for patients with early castration-resistant PCa who received doublet or triplet therapy. Is there a place for Stereotactic Radiotherapy?